Excited to have our study combining Mogamulizumab and EPOCH for frontline treatment of aggressive T cell lymphomas including ATLL and transformed CTCL now open at @SmilowCancer @YaleCancer @YaleHematology #tcelllymphoma #lymsm #rarecancers

Novel chemotherapy-free combinations further amplify glofitamab activity and present promising tailored alternatives to SOC treatments. Read the full article in Blood: https://t.co/uqraAcAxdN

Low-dose Nivolumab and Lenalidomide in Relapsed/Refractory Hodgkin Lym... https://t.co/RJTdusAy3Z. @MathewsVikram @udaypkulkarni @drdatari

Germline CHEK2 variants are identified in 2.2% of cases with early-onset and familial myeloproliferative neoplasms #MPN https://t.co/4NrsCs9MUe

Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for BBB penetration Pola exhibits sign pre-clinical activity V’s PCNSL & SCNSL xenografts & partially penetrates BBB in CNS lymphoma patients w CSF drug conc reaching 0.56% - 1.31% plasma levels

Best #Heme team ever. What a wonderful celebration of our hematology teams in our annual heme team appreciation day. @YaleCancer @Yale @YaleMed @YaleHematology

Outcome of pts w Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy is partic poor: Descar-T Study ⁦@LysaLymphoma⁩ Bispec Abs appear promising offering durable responses c.f to chemotherapy & targeted therapy ⁦@BloodAdvances⁩

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe ⁦@BloodAdvances⁩ ⁦@Kersten_MJ⁩

New online! Optimizing CAR T cell therapy for solid tumours: a clinical perspective

The Biology of MZL subtypes: Challenge and Relevance of Classification

Can’t believe our amazing oncology nurse practitioner Erin Medoff is retiring! She has saved so many lives over the decades & taught me and countless others thru her wisdom and intuitive care for our cancer patients @Dr_AmerZeidan @YaleCancer

Around 20% of patients with DLBCL received 2L treatment, with a 5-year OS of 26%, influenced by age, relapse timing, and treatment intent. https://t.co/f5rKlQSWPS #lymphoidneoplasia

Chronic lymphocytic leukemia (CLL) cells reprogram their tumor microenvironment (TME) to promote drug resistance and tumor progression. Authors 3D approach reveals that CLL B cells upregulate the AP-1 transcription factor, conferring protection against therapy-induced cell death.

Tonight at 7:30pm, Dr. Nikolai Podoltsev @YaleHematology joins #YaleCancerAnswers for a conversation on #leukemia, including AML, ALL, and chronic myeloid leukemia. 🎧Listen live @wnpr 🔁Download @ApplePodcasts 💻Watch @YouTube @SmilowCancer #leukemiaandlymphomaawarenessmonth

Rituximab, bendamustine, and cytarabine followed by venetoclax in olde...

Our annual Review of Advances in Oncology: Highlights from the @ASCO Annual Meeting #ASCO25 begins! We’re looking forward to a full day of updates and connections. @DrRoyHerbstYale @SmilowCancer @YaleMed @YNHH

T follicular helper cells drive antibody response, while B cell help also occurs outside lymphoid follicles in tissues like the lung, CNS, joints, and kidneys. This @YaleIBIO review highlights how tissue T-B helper cells shape infection, #cancer, and autoimmunity.

These are fantastic. Lovely graphics too. I’d only add that Hans IHC, while admittedly imperfect, is a very reasonable surrogate for the increased activity of polatuzumab in ABC LBCL, thus pola-R-CHP is not just one but THE standard of care for patients with non-GCB disease.

How I manage patients with unexplained cytopenia [Apr 10, 2025] Malcovati & Cazzola @BloodPortfolio https://t.co/bfCmp1AJ4R #camoldx #PrecisionMedicine

A study led by @Terri_ParkerMD finds Isatuximab demonstrated substantial efficacy in previously treated patients with #ALamyloidosis and was associated with a good safety profile. https://t.co/WQqUg0c61T @SmilowCancer @BloodPortfolio @YaleHematology

Drug development in MZL: caring for the forgotten child ⁦⁦@BloodPortfolio⁩ ⁦@c_thieblemont⁩ #Sylvain Carras ⁦@ComeBommier⁩